{
    "clinical_study": {
        "@rank": "127735", 
        "arm_group": [
            {
                "arm_group_label": "medical ozone therapy with humares", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "conventional interferon-\u03b1", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy and safety of medical ozone in\n      treatment of chronic hepatitis B patients."
        }, 
        "brief_title": "A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B", 
        "completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "condition": "Chronic Hepatitis B", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "Total of 439 patients with chronic hepatitis B were divided according to patients' intention\n      into two arms. 173 patients in arm I were treated with medical ozone therapy with humares\n      which was made in Germany for at least 12 weeks.266 patients in arm II were treated with\n      conventional interferon-\u03b1 for at least 24 weeks.Patients in both groups were followed-up for\n      24 weeks.Virology response, biochemistry response and hepatitis B viral serological response\n      will be studied at 12 weeks after the treatment, at the end of treatment and after 24 weeks\n      of follow-up."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female\uff1b\n\n          -  HBsAg positive for over 6 months\uff1b\n\n          -  ALT over 2\u00d7ULN, TBIL less than 80 \u00b5mol/L.\n\n        Exclusion Criteria:\n\n          -  Patient has a history of hemorrhagic or hemolysis disease;\n\n          -  Patient has any history of clinical signs/symptoms of hepatic decompensation or\n             serious metabolic hepatic disease;\n\n          -  Patient is co-infected with HIV or HCV;\n\n          -  Patient is treated with anti-virus drug like interferon or nucleoside analogue in\n             recent 6 months;\n\n          -  Patient is treated with immunosuppressive agent for long time, including patient has\n             a history of organ transplantation;\n\n          -  Pregnancy;\n\n          -  Current alcohol or drug abuse;\n\n          -  Difficulty to draw blood through veins;\n\n          -  Patient has a history of carcinoma, or finding suggestive of possible hepatocellular\n             carcinoma (HCC), or AFP over than 100ng/ml;\n\n          -  Patient has a history of any severe physical disease such as cardio-vascular, kidney\n             events, hyperthyroidism or serious electrolyte disturbance;\n\n          -  Patient is enrolled in any other clinical trials."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "12 Years"
        }, 
        "enrollment": {
            "#text": "439", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01887275", 
            "org_study_id": "gyb61641947"
        }, 
        "intervention": [
            {
                "arm_group_label": "medical ozone therapy with humares", 
                "description": "Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20\u00b5g ~40\u00b5g /ml;The second month: 30\u00b5g/ml \u00d7 100ml oxygen- ozone gas \u00d7 100 ml blood;The third month: 20\u00b5g/ml \u00d7 100ml oxygen- ozone gas\u00d7 100 ml blood.", 
                "intervention_name": "medical ozone therapy with humares", 
                "intervention_type": "Device", 
                "other_name": "ozone instrument made in Germany: Humares"
            }, 
            {
                "arm_group_label": "conventional interferon-\u03b1", 
                "description": "Patients in the conventional interferon-\u03b1 treatment group received subcutaneouslly injection of 5 million units of conventional interferon-\u03b1 in three times per week for at least 24 weeks.", 
                "intervention_name": "conventional interferon-\u03b1", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Interferons"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Chronic hepatitis B", 
            "Medical Ozone", 
            "Interferon-\u03b1", 
            "Efficacy"
        ], 
        "lastchanged_date": "June 25, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "GuangZhou", 
                    "country": "China", 
                    "state": "Guangdong", 
                    "zip": "510000"
                }, 
                "name": "Nanfang Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "2", 
        "official_title": "Medical Ozone Versus Conventional Interferon-\u03b1 Treatment of Patients With Chronic Hepatitis B \u2014A Control Study to Evaluate The Efficacy And Safety of Ozone-therapy in Chronic Hepatitis B", 
        "overall_official": {
            "affiliation": "Nanfang Hospital of Southern Medical University", 
            "last_name": "yabing guo, professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "China: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "February 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "To demonstrate the percentage of patients achieving HBV DNA\uff1c1000copies/mL", 
            "measure": "HBV DNA", 
            "safety_issue": "No", 
            "time_frame": "up to 77 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01887275"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Percentage of patients with HBeAg loss and HBeAg seroconversion  in patients with HBeAg positive at baseline.", 
            "measure": "HBeAg", 
            "safety_issue": "No", 
            "time_frame": "up to 77 weeks"
        }, 
        "source": "Nanfang Hospital of Southern Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Nanfang Hospital of Southern Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2010", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2012"
    }
}